MASTERINVEST Kapitalanlage GmbH Invests $5.23 Million in Boston Scientific Corporation $BSX

by · The Cerbat Gem

MASTERINVEST Kapitalanlage GmbH acquired a new stake in Boston Scientific Corporation (NYSE:BSX – Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 48,728 shares of the medical equipment provider’s stock, valued at approximately $5,234,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its position in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares during the period. Boston Partners increased its stake in Boston Scientific by 0.9% during the 1st quarter. Boston Partners now owns 13,235 shares of the medical equipment provider’s stock worth $1,335,000 after purchasing an additional 116 shares in the last quarter. Kovitz Investment Group Partners LLC raised its holdings in Boston Scientific by 78.1% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 35,066 shares of the medical equipment provider’s stock worth $3,537,000 after buying an additional 15,375 shares during the period. Horizon Investments LLC lifted its stake in Boston Scientific by 4.7% in the first quarter. Horizon Investments LLC now owns 23,176 shares of the medical equipment provider’s stock valued at $2,338,000 after buying an additional 1,036 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Boston Scientific by 73.5% in the first quarter. EverSource Wealth Advisors LLC now owns 4,945 shares of the medical equipment provider’s stock valued at $499,000 after buying an additional 2,095 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on BSX. Cowen restated a “buy” rating on shares of Boston Scientific in a report on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $121.00 price target on shares of Boston Scientific in a research note on Friday, October 17th. Leerink Partners upped their price objective on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. UBS Group increased their price objective on Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Finally, Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $124.43.

Read Our Latest Research Report on BSX

Boston Scientific Price Performance

NYSE:BSX opened at $92.58 on Friday. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50. The company has a market cap of $137.24 billion, a P/E ratio of 49.51, a P/E/G ratio of 1.86 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The stock’s 50-day simple moving average is $98.85 and its 200 day simple moving average is $101.61.

Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 143,095 shares of company stock valued at $14,228,950. 0.50% of the stock is owned by corporate insiders.

About Boston Scientific

(Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Featured Articles

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).